Sprache auswählen
Kostenlose Registrierung
Mein Warenkorb

Electrodes

Produktanfrage

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
SHR-A1921SHR-A1921; SHRA1921; SHR-1921Phase 3 ClinicalSolid tumours; Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Salivary Gland Neoplasms; Neoplasms; Breast Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Metastatic breast cancer; Brain metastases; Carcinoma, Non-Small-Cell Lung
Details
ESG-401ESG-401; STI-3258Phase 3 ClinicalShanghai Escugen Biotechnology Co LtdOvarian Neoplasms; Solid tumours; Stomach Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Metastatic breast cancer
Details
OBI-992OBI-992Phase 2 ClinicalObi Pharma Usa IncSolid tumours; Stomach Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Non-Small-Cell Lung
Details
HS-20105HS-20105; HS20105Phase 2 ClinicalHansoh BioMedical R&D CompanySolid tumours
Details
IBI130IBI130; IBI-130Phase 2 ClinicalInnovent Biologics(Suzhou) Co LtdSolid tumours; Neoplasm Metastasis
Details
Anti TROP2 antibody drug conjugate ADC（Fudan University）Phase 2 ClinicalFudan UniversityTriple Negative Breast Neoplasms
Details
9MW-29219MW2921; 9MW-2921Phase 2 ClinicalMabwell (Shanghai) Bioscience Co LtdSolid tumours
Details
MHB036CMHB-036CPhase 2 ClinicalMinghui Pharmaceutical Pty LtdSolid tumours; Lung Neoplasms
Details
BAT-8008BAT-8008; BAT8008Phase 2 ClinicalBio-Thera Solutions LtdSolid tumours; Triple Negative Breast Neoplasms
Details
DB-1305DB1305; BNT325; DB-1305; BNT-325Phase 2 ClinicalSolid tumours
Details
BIO-106BIO-106Phase 2 ClinicalHangzhou Baikai Biopharmaceutical Co LtdSolid tumours; Neoplasms
Details
BL-M02D1Phase 2 ClinicalBaili-Bio (Chengdu) Pharmaceutical Co LtdSolid tumours; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Breast Neoplasms; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung
Details
LCB-84LCB-84Phase 2 ClinicalLegochem Biosciences IncSolid tumours
Details
FDA018 Antibody Drug ConjugateFDA018-ADC; FDA-018-ADCPhase 2 ClinicalShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co LtdSolid tumours; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Neoplasm Metastasis
Details
DAC-002DAC-002; JS-108Phase 1 ClinicalHangzhou Dac Biotech Company LtdSolid tumours; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma
Details
JSKN-016JSKN016; JSKN-016Phase 1 ClinicalJiangsu Alphamab Biopharmaceuticals Co LtdSolid tumours; Neoplasms
Details
DXC-1002DXC1002; DXC-1002Phase 1 ClinicalHangzhou Dac Biotech Company LtdSolid tumours
Details
FZ-AD004FZ-AD004Phase 1 ClinicalShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co LtdSolid tumours
Details
MT-302MT-302Phase 1 ClinicalMyeloid Therapeutics IncCarcinoma; Colonic Neoplasms; Breast Neoplasms; Lung Neoplasms
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
Sacituzumab govitecanIMMU-132; TROP-2-SN-38; IMMU0132; GS-0132; IMMU-0132ApprovedTrodelvy, 拓达维, TRODELVYUnited StatesTriple Negative Breast NeoplasmsImmunomedics Inc2020-04-22Mesothelioma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Thymoma; Brain metastases; Esophageal Squamous Cell Carcinoma; Endometrial Neoplasms; Metastatic breast cancer; Bile Duct Neoplasms; Prostatic Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Klatskin Tumor; Urinary Bladder Neoplasms; Liver Failure; Thyroid Carcinoma, Anaplastic; Salivary Gland Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Glioblastoma; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Biliary Tract Neoplasms; Ovarian Neoplasms; Solid tumours
Details
Sacituzumab tirumotecanSKB-264; MK-2870; SKB264; sac-TMTApprovedKlus Pharma Inc佳泰莱Mainland ChinaTriple Negative Breast NeoplasmsSichuan Kelun-Biotech Biopharmaceutical Co Ltd2024-11-22Triple Negative Breast Neoplasms; Gastrointestinal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Carcinoma, Pancreatic Ductal; Endometrial Neoplasms; Colorectal Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Carcinoma; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Solid tumours
Details
  • Produktanfrage
  • Inverkehr gebrachte Arzneimittelinformation
  • Klinische Arzneimittelinformation
Teilen auf:

Mach mitRechtliche HinweiseSeitenübersichtDatenschutzrichtlinieTerms and Conditions
Website-Feedback
Kontaktieren Sie uns

+49 800 0826645

order.de@acrobiosystems.com
tech.de@acrobiosystems.com

BettinastraBe 30, 60325 Frankfurt am Main